EXFY

Expensify is the classic "good balance sheet, no growth" software stock. Revenue has gone essentially nowhere in five years — $143M in FY2021 to $142M in FY2025 (+2.1% YoY) — despite MD&A's insistence on a "viral, bottom-up, product-led growth" flywheel and an average of 650,000 paid members across 39,700 companies. The engine described in the filing simply isn't producing growth, and gross margin is quietly eroding (gross profit -4.6% YoY to a 50.3% margin). FY2025 GAAP results got worse, not better: net income fell to -$21.4M from -$10.1M, and operating income swung to -$18.0M (a -12.7% operating margin). Part of that self-inflicted decline is the choice, disclosed in MD&A, to fund large-scale brand advertising including a paid placement in Apple's F1 The Movie — the company is spending unscalable marketing dollars to 'maintain market consensus' while revenue stays flat, which is a poor use of capital.

What keeps this from a sell is the quality of the balance sheet and the gap between GAAP and cash. Operating cash flow was +$20.1M against near-zero capex ($17K), so the business threw off roughly $20M of free cash flow despite the reported net loss — the loss is heavily non-cash (D&A $8.46M plus stock comp). The company holds $63.1M cash (up 29%), carries no debt, and equity of $133M against just $53.2M of liabilities (0.40x). Cash alone is ~$0.68/share, or 40% of the $157M market cap, and management bought back $9.1M of stock. At a 1.1x P/S and roughly 8x free cash flow, the downside looks reasonably protected.